A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics

USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.

Table of Contents

Executive SummaryExecutive Summary—Key FindingsExecutive Summary—Key Findings (continued)Key TrendsCompanies to WatchMethodology and ScopeMethodology and ScopeMarket OverviewMarket Overview—IntroductionMarket Overview—EpidemiologyMarket Overview—Epidemiology (continued)Market Overview—Epidemiology (continued)Physicians Treatment GuidelinesPhysicians Treatment GuidelinesPhysicians Treatment Guidelines (continued)Physicians Treatment Guidelines (continued)Physicians Treatment Guidelines (continued)Market SizeMarket Size—SegmentationMarket ForecastMarket SegmentationCompetitive Landscape—ACS Therapeutics (Marketed and Pipeline Products)Competitive Landscape OverviewCompetitive Landscape—Marketed and Pipeline ProductsMarketed Products—Anti-platelet TherapyPipeline Products—Anti-platelet TherapyMarketed Products—Anti-thrombin TherapyMarketed Products—Anti-thrombin Therapy (continued)Pipeline Products—Anti-thrombin TherapyMarketed Products—Anti-hypertensives & Cholesterol Lowering DrugsMarketed Products—Anti-hypertensives & Cholesterol Lowering Drugs (continued)Pipeline Products—Anti-hypertensives & Cholesterol Lowering DrugsPipeline Products—OthersProduct Launch TimelinePatent ExpirationsPivotal Phase 3 TrialsACS Therapeutics—Major Ongoing/Recently Completed Clinical TrialsACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)Summary of Key Products to WatchProduct Dashboard (Key Marketed and Phase 3 Products)Product Dashboard: Plavix (clopidogrel)—Bristol-Myers SquibbProduct Dashboard: Brilinta (ticagrelor)—The Medicines CompanyProduct Dashboard: Angiomax—The Medicines CompanyProduct Dashboard: Zocor (simvastatin)—MerckProduct Dashboard: Xarelto (rivaroxaban)—BayerProduct Dashboard: Alirocumab (RGN727)—Sanofi & RegeneronProduct Dashboard: Evolocumab (Repatha)—AmgenProduct Dashboard: Evacetrapib—Eli Lilly & CompanyProduct Dashboard: Losmapimod—GSKConclusionConclusionsLegal DisclaimerAppendixDecision Support DatabaseDecision Support Database (continued)Decision Support Database (continued)Decision Support Database (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.